### Wegovy Supply Issues in the US Novo Nordisk, the company behind the weight-loss drug Wegovy, is facing supply issues in the United States. They have announced that there will be limited quantities of the 0.25 mg, 0.5 mg, and 1 mg doses available through September. This shortage is due to the supply not meeting the high demand in the US. However, patients already on higher doses (1.7 mg and 2.4 mg) should not be affected. This situation is reminiscent of last year when Wegovy also faced supply shortages. Although there were hopes that the supply issues were resolved by early 2023, the recent announcement shows that the problem persists. The shortage mainly affects new patients who need to start on the lower doses to minimize side effects, especially gastrointestinal issues. Novo Nordisk advises healthcare providers to consider this limited supply when starting new patients on Wegovy. They also caution against using Ozempic, a similar drug for type 2 diabetes, as a substitute for Wegovy. Some weight loss clinics in the US may revert to previous workarounds, such as starting patients on a different drug like liraglutide (Saxenda) and then switching them to a higher dose of Wegovy once it becomes available.